RxDoctor Payments Data

Steven Cohen, MD

Rheumatology · Tyler, TXNPI 1063485886

Payments from drug & device makers

$1,894in general payments, 2019–2025

Across 80 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$482
  • Novartis$314
  • Amgen$277
  • Pfizer$207
  • UCB, Inc.$144
  • GSK$125
  • plus $346 from 9 others

What the payments were for

  • Food & beverage$1,81996%
  • Education$754%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,894 in reported general payments places this provider in the 35th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$167,270
Medicare patients
738
Services billed
2,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab173$1,230,181
Enbrel SureclickEtanercept151$1,111,735
RinvoqUpadacitinib171$1,023,501
EnbrelEtanercept52$576,351
OtezlaApremilast84$451,250
Xeljanz XrTofacitinib Citrate82$448,634
Cosentyx Sensoready PenSecukinumab51$401,925
Humira(Cf)Adalimumab29$308,975
Humira PenAdalimumab18$244,576
HumiraAdalimumab23$163,743
Cosentyx Sensoready (2 Pens)Secukinumab28$146,703
XeljanzTofacitinib Citrate26$134,106
Orencia ClickjectAbatacept24$123,346
BenlystaBelimumab21$94,148
Actemra ActpenTocilizumab25$90,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf), Humira$482$1,496,218223 claims
AmgenEnbrel, Otezla$277$1,027,602136 claims
PfizerXeljanz$207$134,10626 claims
GSKBenlysta$125$94,14821 claims
E.r. Squibb & Sons, L.L.C.Orencia$27$90,10418 claims
UCB, Inc.Cimzia (2 Pack)$144$82,47114 claims
SanofiKevzara$61$38,66713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →